Novartis has been wanting to get its meningitis vaccine Bexsero into the U.S. market. Thanks to an outbreak at Princeton University, that's going to happen sooner than the Swiss drugmaker thought. Ahead of FDA approval, in fact.
Pfizer, which sells the hemophilia drug Xyntha, last year rolled out its HemMobile app to build its relationship with patients who use its treatments. The fact that Pfizer didn't include a version for the BlackBerry goes a long way to explaining why the drug giant is asking its own remaining Blackberry users to turn in those phones.
Nobody making or selling drugs in India was happy when the government this year expanded price caps to nearly 350 drugs, but there seemed little for anyone to do.
New pay-for-delay lawsuits are popping up around the country. Endo Pharma and Actavis have been named, as has AstraZeneca, Teva, Ranbaxy and Dr. Reddy's. And with the U.S. Supreme Court having defined its position this year, the pay-for-delay legal issue is being litigated under a whole new set of rules.
The investigation by Chinese authorities into of a host of drugmakers for bribery has put a chill on business there, but not frozen them in their tracks. Plans announced in the last two days by Johnson & Johnson and Merck KGaA to build new plants in China shows the market is too vast and too important to allow a little uncertainty to put plans on ice.
GlaxoSmithKline expects increasing amounts of business from emerging markets, and so, to get ahead of the curve in India, the company is planning to build a new £85 million ($136.5 million) plant there, CEO Andrew Witty announced while in the country for a conference.
Novartis and Novavax both say they're now able to develop new immunizations within months of a viral strain's identification and sequencing.
While other areas of its business have stumbled, Eli Lilly has been betting on diabetes treatments to help it pull through a bad patch. And like a gambler on a winning streak, Eli Lilly will double down on its investments in insulin production with expansions at plants in China, France, Puerto Rico and the U.S. This is after having doubled its bet earlier this year.
Once again, Merck KGaA reported a quicker-than-expected payoff from its big cost-cutting program. The German drugmaker hiked its profit forecast for the year, saying the changes it has made are delivering cost savings sooner than it had planned.
Teva Pharmaceutical Industries took another shot at fending off early generic competition for its top-selling drug Copaxone. But the U.S. Supreme Court didn't cooperate. The court refused to stay a Federal Circuit ruling that would allow generic rivals onto the market next May, 18 months earlier than Teva had anticipated.
Last week, Bristol-Myers Squibb said it would jettison some research programs, lay off workers and generally reorganize R&D. Now, CEO Lamberto Andreotti is rejigging the commercial side of the business. In the shuffle, current commercial chief Beatrice Cazala will be shunted aside, with current U.S. President Giovanni Caforio taking her place.
Another cancer drug approval, another nosebleed-level price. Johnson & Johnson and Pharmacyclics' breakthrough drug Imbruvica (ibrutinib) won FDA approval yesterday for a rare form of lymphoma. Soon after, the companies said Imbruvica would be priced at more than $90 per pill. At four pills per day, that's about $130,000 per year.
Chile's CFR Pharmaceuticals is threatening to pull its $1.3 billion bid for South African drugmaker Adcock Ingram if the latter's biggest shareholder doesn't come on board with the deal. But CFR chief Alejandro Weinstein is in Johannesburg this week hoping to salvage the deal.
Johnson & Johnson has reportedly wrapped up thousands of lawsuits over faulty hip-replacement products with a hefty $4 billion settlement.
In the drug business, market exclusivity is king. Every branded business model is built on it. But what happens if your brand doesn't have exclusive market access? If you're Sanofi, preparing to launch over-the-counter Nasacort, you sue the FDA.
Will Endo Health Solutions follow in Valeant Pharmaceuticals' footsteps? Already the U.S.-based company has taken one page from Valeant CEO Michael Pearson's playbook, with last week's tax-friendly buyout of Paladin Labs. Can a Valeant-esque series of buyouts be on its way?
New rules for prescribing statin drugs could double the number of people taking them--or not. They could help AstraZeneca pump up sales of its high-powered Crestor--or not. What they will do--most likely--is undercut Merck's cholesterol drugs Vytorin and Zetia, along with AbbVie's fenofibrate-based lipid meds TriCor and Trilipix.
Despite fewer drug approvals overall compared to last year, this year will have turned out a new crop of blockbusters whose combined revenues 5 years out are forecast to reach $18.7 billion, besting last year's record of $16.4 billion in projected sales, according to a report released today by EP Vantage.
Actavis says it's planning to close a plant in North Carolina--and cut 310 jobs in the process.